Cohance Lifesciences · NSE: COHANCE · BSE: 543064
Q2 FY23 results · Jul–Sep 2022
Cohance Lifesciences reported revenue from operations of ₹278.40 crore (down 7.5% from Q2 FY22) and net profit of ₹72.06 crore (down 25.7% from Q2 FY22) for Q2 FY23 (Jul–Sep 2022), on a consolidated basis.
| Item | Q2 FY23 | Q2 FY22 | YoY | Q1 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 278.40 | 300.99 | −7.5% | 338.80 | −17.8% |
| Other income | 10.92 | 5.04 | +116.6% | 11.03 | −1.0% |
| Total income | 289.32 | 306.03 | −5.5% | 349.83 | −17.3% |
| Profit before tax | 98.48 | 116.46 | −15.4% | 148.96 | −33.9% |
| Net profit for the period | 72.06 | 96.98 | −25.7% | 107.54 | −33.0% |
| EPS, basic (₹) | 2.83 | 3.81 | −25.7% | 4.22 | −32.9% |
| Net margin (%) | 25.9 | 32.2 | 31.7 |
| Item | Q2 FY23 | Q2 FY22 | YoY | Q1 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 278.40 | 300.99 | −7.5% | 338.80 | −17.8% |
| Other income | 10.39 | 38.34 | −72.9% | 10.90 | −4.7% |
| Total income | 288.79 | 339.32 | −14.9% | 349.70 | −17.4% |
| Profit before tax | 105.99 | 149.76 | −29.2% | 153.66 | −31.0% |
| Net profit for the period | 78.92 | 115.20 | −31.5% | 114.05 | −30.8% |
| EPS, basic (₹) | 3.10 | 4.53 | −31.6% | 4.48 | −30.8% |
| Net margin (%) | 28.3 | 38.3 | 33.7 |
Consolidated
- Filed with BSE
- 09 Nov 2022, 16:20 IST
- Board meeting
- 08 Nov 2022
- Period
- 01 Jul 2022 to 30 Sep 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 09 Nov 2022, 16:20 IST
- Board meeting
- 08 Nov 2022
- Period
- 01 Jul 2022 to 30 Sep 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE